The World Health Organization (WHO) said there are around 31 Covid-19 vaccine candidates that have entered the human trial phase. As of August 25, six of the candidates have entered phase 3 clinical trials.
These are the 6 Covid-19 vaccine candidates that are currently in phase 3 clinical trials and their estimated cost:
– University of Oxford/ AstraZeneca Vaccine: US$ 4 per dose or approximately Rp. 60,000
– Sinovac vaccine: US$ 5-10 or approximately Rp.72,500 – Rp145,000
– Wuhan Institute of Biological Products/ Sinopharm: US$ 145 per two doses or approximately Rp. 2,100,000
– Beijing Institute of Biological Products/ Sinopharm: US$ 145 per two doses or approximately Rp. 2,100,000
– Moderna/ NIAID: US$ 32 – 37 per dose or approximately Rp. 470,000-550,000
– BioNTech/ FoSun Pharma/ Pfizer: US$ 20 per dose or approximately Rp. 300,000
“Indonesia is one of the 142 vaccine candidates who are in the pre-clinical phase,” said Dr Sunil Bahl from WHO SEARO in the Ending the COVID-19 Pandemic: Efforts and Challenges Webinar on Thursday (27/8).
Vaccine administration is typically carried out in two doses. However, unlike other candidates, the Covid-19 vaccine developed by the University of Oxford only requires one dose.
“Vaccines have their own characteristics, related to the dose, storage conditions, or how fast we can produce (them). This is what distinguishes one type of vaccine from another,” said Dr Bahl.